Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting

Mami Murakami, Horacio Cabral, Yu Matsumoto, Shourong Wu, Mitsunobu Kano, Takao Yamori, Nobuhiro Nishiyama, Kazunori Kataoka

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer. Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromolecules, thereby enhancing the antitumor activity of the nanocarrier-associated drugs. We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability. These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissociated inside each cell. Furthermore, DACHPt/m selectively dissociated within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase. Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors. These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clinical applications.

Original languageEnglish
Article number64ra2
JournalScience Translational Medicine
Volume3
Issue number64
DOIs
Publication statusPublished - Jan 5 2011
Externally publishedYes

Fingerprint

oxaliplatin
Micelles
Platinum
Pharmaceutical Preparations
Neoplasms
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Vascular Tissue Neoplasms
Metallothionein
Endosomes
Drug Delivery Systems
Ovarian Neoplasms
Permeability
Fluorescence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. / Murakami, Mami; Cabral, Horacio; Matsumoto, Yu; Wu, Shourong; Kano, Mitsunobu; Yamori, Takao; Nishiyama, Nobuhiro; Kataoka, Kazunori.

In: Science Translational Medicine, Vol. 3, No. 64, 64ra2, 05.01.2011.

Research output: Contribution to journalArticle

Murakami, M, Cabral, H, Matsumoto, Y, Wu, S, Kano, M, Yamori, T, Nishiyama, N & Kataoka, K 2011, 'Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting', Science Translational Medicine, vol. 3, no. 64, 64ra2. https://doi.org/10.1126/scitranslmed.3001385
Murakami, Mami ; Cabral, Horacio ; Matsumoto, Yu ; Wu, Shourong ; Kano, Mitsunobu ; Yamori, Takao ; Nishiyama, Nobuhiro ; Kataoka, Kazunori. / Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. In: Science Translational Medicine. 2011 ; Vol. 3, No. 64.
@article{2461977448104437880483b736b4c0d0,
title = "Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting",
abstract = "Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer. Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromolecules, thereby enhancing the antitumor activity of the nanocarrier-associated drugs. We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability. These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissociated inside each cell. Furthermore, DACHPt/m selectively dissociated within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase. Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors. These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clinical applications.",
author = "Mami Murakami and Horacio Cabral and Yu Matsumoto and Shourong Wu and Mitsunobu Kano and Takao Yamori and Nobuhiro Nishiyama and Kazunori Kataoka",
year = "2011",
month = "1",
day = "5",
doi = "10.1126/scitranslmed.3001385",
language = "English",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "64",

}

TY - JOUR

T1 - Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting

AU - Murakami, Mami

AU - Cabral, Horacio

AU - Matsumoto, Yu

AU - Wu, Shourong

AU - Kano, Mitsunobu

AU - Yamori, Takao

AU - Nishiyama, Nobuhiro

AU - Kataoka, Kazunori

PY - 2011/1/5

Y1 - 2011/1/5

N2 - Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer. Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromolecules, thereby enhancing the antitumor activity of the nanocarrier-associated drugs. We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability. These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissociated inside each cell. Furthermore, DACHPt/m selectively dissociated within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase. Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors. These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clinical applications.

AB - Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer. Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromolecules, thereby enhancing the antitumor activity of the nanocarrier-associated drugs. We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability. These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissociated inside each cell. Furthermore, DACHPt/m selectively dissociated within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase. Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors. These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=78650954706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650954706&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3001385

DO - 10.1126/scitranslmed.3001385

M3 - Article

C2 - 21209412

AN - SCOPUS:78650954706

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 64

M1 - 64ra2

ER -